Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
Authors:
Open Access
- 4 February 2023
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 57, 101827
Abstract
No abstract availableKeywords
Funding Information
- Gloria Borges WunderGlo Foundation
- National Natural Science Foundation of China (82202892)
- China Postdoctoral Science Foundation (2022M710768)
- National Postdoctoral Program for Innovative Talents (BX20220084)
- Dhont Family Foundation
- National Cancer Institute (P30CA 014089)
This publication has 30 references indexed in Scilit:
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- A global reference for human genetic variationNature, 2015
- Genome-wide association study of colorectal cancer identifies six new susceptibility lociNature Communications, 2015
- Genetic variants in de novo lipogenic pathway genes predict the prognosis of surgically-treated hepatocellular carcinomaScientific Reports, 2015
- Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy WithdrawalCell Metabolism, 2014
- Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapyMedical Oncology, 2013
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Fatty acid metabolism: target for metabolic syndromeJournal of Lipid Research, 2009
- Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancerJournal of Molecular Medicine, 2008
- Increased Risk of Colorectal Cancer Due to Interactions Between Meat Consumption and the CD36 Gene A52C Polymorphism Among JapaneseNutrition and Cancer, 2005